Dyadic announces Q3 2026 financial results, including first direct commercial sales
Dyadic reported the first quarter with direct sales of recombinant proteins and highlighted strategic partnership expansion, marked by Proliant's AlbuFree DX promotion and Inzymes commercializing a second product.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed